Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
about
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesEffect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host TargetsCost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Non-healthcare costs of hepatitis C: A systematic review.The impact of hepatitis C virus outside the liver: Evidence from Asia.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.COST-EFFECTIVE OPTIONS FOR THE PREVENTION AND MANAGEMENT OF GASTROINTESTINAL AND LIVER DISEASE IN THE ASIA-PACIFIC REGION.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based EvidenceHepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatmentEfficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
P2860
Q26749246-894AF554-B39A-4CE5-BBE3-16B8470A61A2Q27468855-6B3E0209-F973-4CA1-A6D7-E51103DE2CE2Q33698956-9243079E-54AF-45CD-86A0-7A747A0EBF83Q37578288-D76C235A-DAD9-408B-8FB6-C7168CAC3297Q38606907-B6B94A41-1F70-4C1E-A750-0468BFE2DFEDQ38982462-95A65B1C-8B95-469B-BC39-B2FD1B9E0DB9Q39102936-BDC42ECC-7367-43A1-8B46-BCD9238043D1Q39137372-4C586417-F7DA-468C-AF39-03D1EC9F9BEEQ40072613-722A3C64-2007-45DC-BDFC-ED4E5AF536BEQ40082765-F4C08C94-E281-4193-BB5B-AD594CF48A2CQ40129813-E37CBC0D-888D-4D9C-9AA3-69F73C1E7BECQ41925862-C080CF8A-BC48-4C86-A3F8-E4C21D063157Q42048758-0C4BE536-CE70-49C9-B6B5-1C21A8C444A5Q48062582-AFA46C1D-BB5D-4B02-89FD-598AE230A4D9Q48111916-18284C15-382E-440D-82F2-CF4CD72424D9Q50262230-6875AE0D-CD28-49BA-9E18-441D5103EACBQ55280669-B309E5C7-28FD-48DC-8DBF-7A32C102666BQ57145115-7217FD4E-998C-4CF3-8CB8-35ABF7C924B9Q57167190-D3D67313-7072-4530-B79E-F241E09CB7B6Q57827106-DA13B0A0-3E34-4C84-9A28-97E5145FE5D2
P2860
Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Systematic Review of Modelling ...... with Direct-Acting Antivirals.
@en
type
label
Systematic Review of Modelling ...... with Direct-Acting Antivirals.
@en
prefLabel
Systematic Review of Modelling ...... with Direct-Acting Antivirals.
@en
P2860
P1433
P1476
Systematic Review of Modelling ...... with Direct-Acting Antivirals.
@en
P2093
Jagpreet Chhatwal
Tianhua He
P2860
P2888
P304
P356
10.1007/S40273-015-0373-9
P577
2016-01-09T00:00:00Z